Management of aggressive, usually late-occurring, post-transplant lymphoproliferative disorders (PTLDs), a life-threatening complication after solid organ transplants, remains controversial. Four children affected by aggressive CD20+ PTLDs received a chemo-immunotherapy regimen for remission induction based on fludarabine, cyclophosphamide, doxorubicin, and rituximab, associated with a rapid discontinuation of immunosuppression (IS). Subsequent consolidation chemotherapy consisted of Berlin-Frankfurt-Münster-modified blocks. All patients achieved a complete remission, which persisted for 25, 68+, 80+, and 103+ months after diagnosis. Therapy was well tolerated. No patients developed allograft rejection during PTLD treatment. Our experience suggests that this chemo-immunotherapeutic approach may be an effective treatment strategy while allowing for a concomitant discontinuation of IS. © 2011 Wiley-Liss, Inc.
Giraldi, E., Provenzi, M., Fiocchi, R., Colledan, M., Cornelli, P., Torre, G., et al. (2011). Fludarabine, Cyclophosphamide, Doxorubicin (FCD), and Rituximab: A Remission Induction Therapy for Aggressive Pediatric Post-Transplant Lymphoproliferative Disease (PTLD). PEDIATRIC BLOOD & CANCER, 57(2), 324-328 [10.1002/pbc.23004].
Fludarabine, Cyclophosphamide, Doxorubicin (FCD), and Rituximab: A Remission Induction Therapy for Aggressive Pediatric Post-Transplant Lymphoproliferative Disease (PTLD)
Colledan M;
2011
Abstract
Management of aggressive, usually late-occurring, post-transplant lymphoproliferative disorders (PTLDs), a life-threatening complication after solid organ transplants, remains controversial. Four children affected by aggressive CD20+ PTLDs received a chemo-immunotherapy regimen for remission induction based on fludarabine, cyclophosphamide, doxorubicin, and rituximab, associated with a rapid discontinuation of immunosuppression (IS). Subsequent consolidation chemotherapy consisted of Berlin-Frankfurt-Münster-modified blocks. All patients achieved a complete remission, which persisted for 25, 68+, 80+, and 103+ months after diagnosis. Therapy was well tolerated. No patients developed allograft rejection during PTLD treatment. Our experience suggests that this chemo-immunotherapeutic approach may be an effective treatment strategy while allowing for a concomitant discontinuation of IS. © 2011 Wiley-Liss, Inc.File | Dimensione | Formato | |
---|---|---|---|
chemio ptld ped.pdf
Solo gestori archivio
Dimensione
74.09 kB
Formato
Adobe PDF
|
74.09 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.